Brian Druker, M.D., OHSU Knight Cancer Institute, discusses how the Author: LLS Oncology Tube, 1 week ago
LLS launches collaborative clinical trial for acute myeloid leukemia - Pharmaceutical Business Review, 1 week ago
Precision Clinical Trial Aims to Find First New Treatment for AML in More than 40 Years - CURE Magazine, 1 week ago
Thousands of runners will hit the streets of Chicago this weekend for the 2016 Chicago Marathon. Before they cross the start and finish lines, they will go through an intense training program to meet one of their most challenging goals: 26.2 miles. ...LLS Community, 1 day ago
The Beat AML Master Trial Study Design: Observational, prospective cohort study Study Start Date: November 2016 Estimated Study Completion Date: November 2023 Study Status: Currently recruiting participants Estimated Enrollment: 500 Sponsor: ...ASH Clinical News, 1 day ago
James P. Allison, PhD James P. Allison, PhD, was recently presented with the Association of American Cancer Institutes (AACI) Distinguished Scientist Award in recognition of his extraordinary scientific accomplishments and contributions to cancer ...Targeted Oncology, 1 day ago
Mark A. Gregory a , b , 1 , Angelo DAlessandro a , b , Francesca Alvarez-Calderon b , c , Jihye Kim b , d , Travis Nemkov a , b , Biniam Adane b , e , Andrii I. Rozhok a , b , Amit Kumar f , Vijay Kumar f , Daniel A. Pollyea b , e , ...PNAS, 3 days ago
PORTLAND, Ore. Today OHSU announced Mark B. Williams has accepted the role of chief strategy officer for the OHSU Knight Cancer Institute. This is a new position focused on overseeing the budget and long-term financial sustainability of the Knight ...BioSpace, 4 days ago
It was at the tail end of 2001 when Joannie Clements decided shed had enough. For six months, she had suffered severe and unusual bruising, fatigue, extreme weight loss, eye bleeds, unusual infections, loss of appetite, inability to smell or taste, ...CURE Magazine, 1 week ago
With 20 Agents, 803 Trials, and 166,736 Patient Slots, Is Pharma Investing Too Heavily in PD-1 Drug Development?
publication date: Oct. 7, 2016 By Laura Brawley Pharmaceutical companies are betting big on cancer immunotherapies that rely on the PD-1 protein and its ligands, PD-L1 and PD-L2, to initiate an immune response. The rush to develop these ...Cancer Letter.com, 2 weeks ago
PRWeb To celebrate Breast Cancer Awareness Month, all Dutch Bros Coffee locations will donate proceeds from the sale of its specialty "Be Aware" travel mugs to the advancement of breast cancer research at Oregon Health Sciences University Knight ...Minyanville, 3 weeks ago
More from: , PRWeb...and 5 other sources
Microsoft has revealed its involvement in several collaborations with scientists to help fight or, as it puts it, "solve" cancer using artificial intelligence. Microsoft says it aims to help oncologists consider the individual elements of each ...ZDNet, 1 month ago Microsoft Develops AI to Help Cancer Doctors Find the Right Treatments Bloomberg, 1 month ago
More from: , Naija247News...and 5 other sources
on your WebpageAdd Widget >Get your members hooked!